Neurix specializes in the development of advanced human cellular model systems aimed at enhancing drug discovery and neuroscience research. The company focuses on creating physiologically relevant 3D neural tissues derived from human pluripotent stem cells, which closely mimic native brain tissue. Their innovative organoid models, such as MiniBrain™ and Neurosphere, are designed for high-throughput screening and disease modeling, allowing researchers to conduct efficient and reproducible studies. Neurix's offerings include a range of services for drug efficacy testing, including glioblastoma invasion models and gene therapy assessments, which facilitate the evaluation of therapeutic interventions in a controlled environment.

In addition to their core technologies, Neurix is actively involved in various international collaborations aimed at addressing complex neurological conditions such as Multiple Sclerosis and Alzheimer's disease. The company is developing in vitro models that target neurorepair and myelination for Multiple Sclerosis, as well as 3D human in vitro models for Alzheimer's disease that utilize newly identified blood biomarkers for diagnostics. Neurix's commitment to innovation is further exemplified by their participation in projects focused on Guillain-Barré Syndrome and Chronic Septic Granulomatosis, where they leverage patient-derived stem cells to advance therapeutic development. Through these initiatives, Neurix aims to revolutionize the landscape of neurological research and treatment.

Switzerland

To help get better and safer medicines to patients faster. We developed a robust technology and translated it into a unique product which today serves as the gold standard for in vitro testing of products and pharmaceuticals.

Neurix

Company Details